StreetAlpha.app
Home › Stocks › NPCE

NeuroPace Inc (NPCE)

$8.20
▲ +2.89%
LAST CLOSE · NOV 17

NeuroPace makes the RNS System, an implanted brain device that treats seizures in people with epilepsy. It last closed at $8.20 on Nov 17, up 2.89% on the day. NPCE last reported earnings on Thu, Nov 12, 2026. The average 12-month price target from 6 analysts is $11.00 (+34.1% from the last close), with a high of $14.00 and a low of $7.00. Analyst consensus is Buy, based on the latest ratings from 6 firms (4 buy, 2 hold, 0 sell).

AI Auto Pilots
Is NPCE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$106.7M
+29.2% vs a year ago
Net income
−$18.9M
−17.7% margin
EPS (diluted)
−$0.56
Free cash flow
−$12.4M
−11.6% margin
Valuation
Market cap
$282.5M
34.5M shares
P/E
–
No P/E while losing money
Price to sales
2.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.2M
At Sep 30
Debt
$59.2M
At Sep 30
Shareholder equity
$11.5M
Shares outstanding
34.5M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $45.2M$45.2MFY2021FY2022: $45.5M$45.5MFY2022FY2023: $65.4M$65.4MFY2023FY2024: $79.9M$79.9MFY2024FY2025: $100.0M$100.0MFY2025

From NPCE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · After the close (AMC)
Reported EPS
-$0.10
vs -$0.14 est. · beat
Year-ago EPS
-$0.11
Same quarter last year
Options-implied move
±13.3%
Priced in before that report
Analyst consensus
Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
6firms
4 Buy2 Hold0 Sell
Each firm's latest rating on NPCE in the past 90 days
Average 12-month target
$11.00
▲ 34.1% upside

Based on 6 analysts who set a price target on NPCE in the past 90 days. The average target is $11.00, with a high of $14.00 and a low of $7.00, compared with the last close of $8.20.

Low $7.00Avg $11.00High $14.00
Blue marker: last close $8.20
Highest target$14.00
Average target$11.00
Lowest target$7.00
Latest rating changes
MizuhoTarget lowered
Nov 16Buy$22 → $12
HC Wainwright & Co.Target lowered
Nov 16Buy$20 → $12
Cantor FitzgeraldMaintained
Nov 16Buy$12
JP MorganDowngrade
Nov 13Hold$9
KeybancTarget lowered
Nov 13Buy$18 → $14
DateFirmActionRatingPrice target
Nov 16MizuhoTarget loweredBuy$22 → $12
Nov 16HC Wainwright & Co.Target loweredBuy$20 → $12
Nov 16Cantor FitzgeraldMaintainedBuy$12
Nov 13JP MorganDowngradeHold$9
Nov 13KeybancTarget loweredBuy$18 → $14
Loading…

Technical Analysis

NPCE · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 47% below its 20 day and 58% below its 50 day average. It is 79% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the Pivot S1 at $7.71, and the nearest resistance the Pivot R1 at $8.68.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.3%/day
Key levels
$19.6052 week high+139.0%
$14.69200 day average+79.1%
$14.01100 day average+70.9%
$13.27Swing high (Oct 13)+61.8%
$12.9450 day average+57.8%
$12.0320 day average+46.7%
$8.68Pivot R1+5.9%
$8.20Pivot+0.0%
$8.20Last close
$7.71Pivot S1−6.0%
$5.4752 week low−33.3%
Indicators
RSI (14)26.46Oversold below 30Oversold
MACD-1.05Below its signal lineBearish
Stochastic28.8Middle of its rangeNeutral
ADX (14)20.1Weak trend
Williams %R-67.8Oversold below −80, overbought above −20Neutral
CCI (20)-193.0Oversold below −100, overbought above 100Oversold
Rate of change−33.4%Change over 10 sessionsBearish
ATR (14)$1.09Typical daily range, 13.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NPCE

What happened before

See how NPCE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NPCE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NPCE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NPCE in the last 90 days.

Loading…

See today’s whale options flow across the market →

NPCE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼47 buying vs 68 selling
  • ▲Held by funds +0.7 pts
  • ▼Funds holding -8
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding105113−7.1%
In funds' top 1000–
Held by funds77.8%77.2%+0.7 pts
New / increased14 / 3318 / 48−28.8%
Reduced / sold out45 / 2336 / 18+25.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NPCE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NPCE is in one of them and how their past NPCE trades turned out.

NPCE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NPCE in an article yet. Here's the latest on the wider market.

About NeuroPace

NeuroPace makes medical devices for people with epilepsy, focusing on those whose seizures are not controlled by medication. Its main product is the RNS System, an implant that monitors the brain's electrical activity and delivers small electrical pulses when it detects a seizure starting. The devices are sold mainly to epileptologists and neurosurgeons who treat patients at specialized epilepsy centers in the United States. The company is based in Mountain View, California.

Headquarters
Mountain View, CA